• Advocacy

     
     
     
    Type Size
     

    FDA Issues Safety Alert on Zocor

    March 22, 2010

    FDA is notifying healthcare professionals and patients that, based on review of data from a large clinical trial and other sources, there is an increased risk of muscle injury in patients taking the highest approved dose of the cholesterol-lowering medication, Zocor (simvastatin) 80 mg, compared to patients taking lower doses of simvastatin and possibly other drugs in the "statin" class. FDA is also reviewing data from other clinical trials, observational studies, adverse event reports, and data on prescription use of simvastatin to better understand the relationship between high-dose simvastatin use and muscle injury.

    Simvastatin is sold as a single-ingredient generic medication and as the brand-name, Zocor. It is also sold in combination with ezetimibe as Vytorin; and niacin as Simcor.

    CLICK HERE for FDA's recommendations for healthcare professionals, recommendations for patients and a data summary of information used in this ongoing review.

    CLICK HERE for prescribing information for Zocor